| Name | Title | Contact Details |
|---|
Chem Rx Corporation, formerly Paramount Acquisition Corp., provides institutional pharmacy services to skilled nursing facilities, assisted living facilities, residential living facilities, addiction treatment centers and other long-term healthcare
ITC is a wholly-owned subsidiary of Thoratec and develops, manufactures and markets medical devices used in three distinct segments of the medical field.
Signify Health exists to drive more healthy, happy days at home. That`s why we`re committed to accelerating the movement to value-based care, transforming how care is paid for and delivered, and sharing accountability for driving better outcomes for the individuals and families we all serve. Today, Signify Health is privileged to impact the lives of millions of people every year. Our high-performance provider and community networks—which includes the nation`s largest field-based network of doctors and nurse practitioners—reaches and engages people anywhere in the U.S. With powerful analytics and clinical expertise, we support individuals` health journeys from the acute care facility to the ideal next site of care and all the way to a place of residence, helping them get home sooner and stay there longer. This is how we`re transforming a fragmented healthcare system into one that`s value-based, human-centered, and drives more healthy and happy days at home.
Cardio-Respiratory Assistance is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic